Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but ...

Today, Incubate and the National Security Commission on Emerging Biotechnology (NSCEB) convened venture capital investors, NSCEB commissioners and staff, and congressional offices on Capitol Hill for ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Quick Read Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year ...

Biotechnology drives cutting-edge medical innovation but is constrained by Europe’s fragmented regulatory landscape. The Biotech Act offers a critical opportunity to remove structural barriers, ...

Convertible bonds can be enticing for biotech companies since they offer less dilutive financing than equity offerings and often carry low interest rates.

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech’s New York Reference Laboratory DUBLIN and NEW YORK, ...